EP17.23: The connection between first trimester biochemical screening results and the risk of neonatal complications post‐delivery

The study aimed to correlate the outcomes of biochemical tests initially used for assessing the risk of fetal chromosomal aberrations (Pregnancy-Associated Plasma Protein-A [PAPP-A] and free beta-human Chorionic Gonadotropin [fβ-hCG]) collected between the 11th and 13+6 weeks of gestation with the risk of neonatal complications in newborns. We included patients who underwent prenatal screening in the first trimester of pregnancy between the 11th and 13+6 weeks of gestation, followed by a follow-up until delivery. We recorded the incidence of neonatal complications such as severe and moderate newborn condition at 1 minute postbirth (Apgar score < 8), and admission to the Neonatal Intensive Care Unit (NICU). The study encompassed 742 patients, and the results are presented in table 1. Mothers of newborns with a poorer clinical condition at birth had a statistically lower median concentration of PAPP-A and PAPP-A MoM in the first trimester of pregnancy. We observed that newborns with lower concentrations of free β-hCG and β-hCG MoM in the first trimester had an increased risk of hospitalization in the NICU. Low concentrations of free β-hCG in the first trimester of pregnancy may be associated with neonatal hospitalization in the NICU. Lower PAPP-A concentrations might be linked with poorer neonatal outcomes, as assessed by the Apgar score.